Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy

Journal of Pathology

Volumn 232, Issue 4, 2014, Pages 473-481

  Wu, Ren Chin ^a,e   Ayhan, Ayse ^b   Maeda, Daichi ^c   Kim, Kyu Rae ^d   Clarke, Blaise A ^f   Shaw, Patricia ^f   Chui, Michael Herman ^f   Rosen, Barry ^f   Shih, Ie Ming ^a   Wang, Tian Li ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b SEIREI MIKATAHARA GENERAL HOSPITAL   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d Asan Medical Center   (South Korea)

^e CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^f TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

ARID1A; clear cell carcinoma; PIK3CA; telomerase; telomere; TERT promoter

Indexed keywords

MESSENGER RNA; RETINOBLASTOMA BINDING PROTEIN 2; TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CLEAR CELL CARCINOMA; DISEASE SPECIFIC SURVIVAL; ENDOMETRIOSIS; FEMALE; GENE EXPRESSION; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE AGED; MUTATIONAL ANALYSIS; OVARY CARCINOMA; OVERALL SURVIVAL; PIK3CA GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SOMATIC MUTATION; TELOMERASE REVERSE TRANSCRIPTASE GENE; TELOMERE; TELOMERE HOMEOSTASIS; TUMOR GROWTH;

ARID1A; CLEAR CELL CARCINOMA; PIK3CA; TELOMERASE; TELOMERE; TERT PROMOTER;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; BALTIMORE; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; ONTARIO; OVARIAN NEOPLASMS; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROMOTER REGIONS, GENETIC; REPUBLIC OF KOREA; RNA, MESSENGER; TELOMERASE; TRANSCRIPTION FACTORS;

EID: 84893848699     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4315     Document Type: Article

References (44)

1. de Lange T., How telomeres solve the end-protection problem. Science 2009; 326: 948-952.
2. Prieur A, Peeper DS,. Cellular senescence in vivo: a barrier to tumorigenesis. Curr Opin Cell Biol 2008; 20: 150-155.
3. Artandi SE, DePinho RA,. Telomeres and telomerase in cancer. Carcinogenesis 2010; 31: 9-18.
4. Harley CB,. Telomerase and cancer therapeutics. Nat Rev Cancer 2008; 8: 167-179. (Pubitemid 351305939)
5. Pirker C, Holzmann K, Spiegl-Kreinecker S, et al., Chromosomal imbalances in primary and metastatic melanomas: over-representation of essential telomerase genes. Melanoma Res 2003; 13: 483-492. (Pubitemid 37266951)
6. Dalla-Favera R, Wu K-J, Grandori C, et al., Direct activation of TERT transcription by c-MYC. Nat Genet 1999; 21: 220-224. (Pubitemid 29070372)
7. Castelo-Branco P, Choufani S, Mack S, et al., Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. Lancet Oncol 2013; 14: 534-542.
8. Heaphy CM, Subhawong AP, Hong S-M, et al., Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 2011; 179: 1608-1615.
9. Henson J, Neumann A, Yeager T,. Alternative lengthening of telomeres in mammalian cells. Oncogene 2002; 21: 598-610. (Pubitemid 34146260)
10. Horn S, Figl A, Rachakonda PS, et al., TERT promoter mutations in familial and sporadic melanoma. Science 2013; 339: 959-961.
11. Huang FW, Hodis E, Xu MJ, et al., Highly recurrent TERT promoter mutations in human melanoma. Science 2013; 339: 957-959.
12. Killela PJ, Reitman ZJ, Jiao Y, et al., TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 2013; 110: 6021-6026.
13. Liu X, Wu G, Shan Y, et al., Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle 2013; 12: 1637-1638.
14. Vinagre J, Almeida A, Põpulo H, et al., Frequency of TERT promoter mutations in human cancers. Nat Commun 2013; 4: 2185.
15. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
16. Jones S, Wang T-L, Kurman RJ, et al., Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol 2012; 226: 413-420.
17. Jones S, Wang T-L, Shih I-M, et al., Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010; 330: 228-231.
18. Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67-73.
19. Kuhn E, Wu R-C, Guan B, et al., Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst 2012; 104: 1503-1513.
20. Kuhn E, Meeker AK, Visvanathan K, et al., Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma. Mod Pathol 2011; 24: 1139-1145.
21. Maeda D, Mao T-L, Fukayama M, et al., Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int J Mol Sci 2010; 11: 5120-5128.
22. Ayhan A, Mao T-L, Seckin T, et al., Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer 2012; 22: 1310-1315.
23. Kuo K-T, Mao T-L, Jones S, et al., Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009; 174: 1597-1601.
24. Viganõ P, Somigliana E, Chiodo I, et al., Molecular mechanisms and biological plausibility underlying the malignant transformation of endometriosis: a critical analysis. Hum Reprod Update 2006; 12: 77-89. (Pubitemid 43013749)
25. Wiegand KC, Shah SP, Al-Agha OM, et al., ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363: 1532-1543.
26. Tan DSP, Kaye S,. Ovarian clear cell adenocarcinoma: a continuing enigma. J Clin Pathol 2007; 60: 355-360. (Pubitemid 46596552)
27. Tsuchiya A, Sakamoto M, Yasuda J, et al., Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1β as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 2003; 163: 2503-2512. (Pubitemid 37466491)
28. Sharrocks AD,. The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2001; 2: 827-837. (Pubitemid 33674083)
29. Seth A, Watson DK,. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 2005; 41: 2462-2478. (Pubitemid 41540623)
30. Sato N, Tsunoda H, Nishida M, et al., Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000; 60: 7052-7056. (Pubitemid 32059184)
31. Yamamoto S, Tsuda H, Takano M, et al., Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol 2011; 25: 615-624.
32. Yamamoto S, Tsuda H, Takano M, et al., PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J Pathol 2011; 225: 189-194.
33. Ishikawa F., Telomere crisis, the driving force in cancer cell evolution. Biochem Biophys Res Commun 1997; 230: 1-6. (Pubitemid 27210232)
34. Campbell PJ,. Telomeres and cancer: from crisis to stability to crisis to stability. Cell 2012; 148: 633-635.
35. Singh AM, Reynolds D, Cliff T, et al., Signaling network crosstalk in human pluripotent cells: a Smad2/3-regulated switch that controls the balance between self-renewal and differentiation. Cell Stem Cell 2012; 10: 312-326.
36. Dubrovska A, Kim S, Salamone RJ, et al., The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 2009; 106: 268-273.
37. Li H, Gao Q, Guo L, et al., The PTEN/PI3K/Akt pathway regulates stem-like cells in primary esophageal carcinoma cells. Cancer Biol Ther 2011; 11: 950-958.
38. Bleau A-M, Hambardzumyan D, Ozawa T, et al., PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009; 4: 226-235.
39. Lin Y, Yang Y, Li W, et al., Reciprocal regulation of Akt and Oct4 promotes the self-renewal and survival of embryonal carcinoma cells. Mol Cell 2012; 48: 627-640.
40. Kang SS, Kwon T, Kwon DY, et al., Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem 1999; 274: 13085-13090.
41. Bellon M, Nicot C,. Central role of PI3K in transcriptional activation of hTERT in HTLV-I-infected cells. Blood 2008; 112: 2946-2955.
42. Heeg S, Hirt N, Queisser A, et al., EGFR overexpression induces activation of telomerase via PI3K/AKT-mediated phosphorylation and transcriptional regulation through Hif1α in a cellular model of oral-esophageal carcinogenesis. Cancer Sci 2011; 102: 351-360.
43. Yang K, Zheng D, Deng X, et al., Lysophosphatidic acid activates telomerase in ovarian cancer cells through hypoxia-inducible factor-1α and the PI3K pathway. J Cell Biochem 2008; 105: 1194-1201.
44. Hakin-Smith V, Jellinek DA, Levy D, et al., Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 2003; 361: 836-838. (Pubitemid 36331849)